NCT05038904View on ClinicalTrials.gov

Preventing Anaphylaxis With Acalabrutinib

PHASE2CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

December 16, 2021

Primary Completion Date

December 8, 2022

Study Completion Date

December 31, 2022

Conditions

Food AllergyFood Allergy Peanut

Interventions

DRUG

Acalabrutinib

100 mg oral capsule

Trial Locations (1)

21224

Johns Hopkins Bayview Medical Center, Baltimore

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

Johns Hopkins University

OTHER